First Heartland Consultants’s Seelos Therapeutics, Inc. Common Stock SEEL Stock Holding History

First Heartland Consultants’s Portfolio SEEL Stock Details SEEL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q4	–	Sell	-8	Closed	-$5K	–	390
2023 Q3	$5K	Hold	8	–	–	﹤0.01%	377
2023 Q2	$34.9K	Hold	8	–	–	﹤0.01%	372
2023 Q1	$20.2K	Hold	8	–	–	﹤0.01%	355
2022 Q4	$20.6K	Hold	8	–	–	﹤0.01%	371
2022 Q3	$31	Hold	8	–	–	﹤0.01%	344
2022 Q2	$20K	Hold	8	–	–	﹤0.01%	341
2022 Q1	$24K	Buy	8 +4	+100%	+$17.2K	﹤0.01%	347
2021 Q4	$23	Buy	4 +1	+33%	+$7.68K	﹤0.01%	368
2021 Q3	$30K	Hold	3	–	–	﹤0.01%	385
2021 Q2	$30K	Buy	+3	New	+$49.3K	﹤0.01%	381

Other funds holding SEEL

Mirae Asset Global Investments Seoul, South Korea $67.7B AUM 51.91% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return

Wealth Effects Boston, Massachusetts $282M AUM 62.81% 1-Year Est. Return

AdvisorShares Investments Bethesda, Maryland $549M AUM 32.58% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

GJL

Gendell Jeffrey L $7.34B AUM 183.72% 1-Year Est. Return

MWM

Modera Wealth Management Westwood, New Jersey $8.34B AUM 19.68% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

First Heartland Consultants's SEEL Position: Q4 2023 in Review

First Heartland Consultants sold out of Seelos Therapeutics, Inc. Common Stock (SEEL) in Q4 2023, closing a stake of 8 shares — an estimated $5K sold.

First Heartland Consultants first reported a position in SEEL in Q2 2021 and held it in 10 quarters. The position peaked at $34.9K in Q2 2023. 32 funds tracked by Wall St. Rank hold SEEL as of Q4 2023.

First Heartland Consultants reported no remaining Seelos Therapeutics, Inc. Common Stock position as of Q4 2023 after selling out during the quarter.
First Heartland Consultants sold 8 Seelos Therapeutics, Inc. Common Stock shares in Q4 2023, an estimated $5K.
First Heartland Consultants first reported a position in Seelos Therapeutics, Inc. Common Stock in Q2 2021 and held it in 10 quarters.
First Heartland Consultants's Seelos Therapeutics, Inc. Common Stock position peaked at $34.9K in Q2 2023.
32 funds tracked by Wall St. Rank held Seelos Therapeutics, Inc. Common Stock as of Q4 2023.

Based on First Heartland Consultants's 13F filing for Q4 2023, filed 8 Feb 2024.